Press Releases

Date Title
August 7, 2019 Progenity Announces Appointment of Brian Kotzin, M.D., to its Board of Directors
Dr. Kotzin’s experience in the development of novel biotherapeutics, especially in autoimmune and inflammatory diseases, will provide valuable guidance as the company advances its pipeline of precision therapeutics/biotherapeutics and diagnostics. SAN DIEGO, August 7, 2019  – Progenity, Inc., a
June 25, 2019 NYU Winthrop and Progenity Collaborate to Develop Diagnostic Test to Assess Risk for Preterm Birth
Announcing a collaborative research and development initiative for women’s health with a focus on preterm births. Mineola, NY and San Diego, CA  – NYU Winthrop Hospital and Progenity, Inc., today announced a collaborative research and development initiative for women’s health with a focus on
June 11, 2019 Progenity to Present at Raymond James Life Sciences and MedTech Conference
Participating in New York, June 18 and 19. SAN DIEGO, June 11, 2019  – We will be participating in the Raymond James Life Sciences and MedTech Conference in New York, June 18 and 19. Chief Executive Officer Harry Stylli, Ph.D., will present a corporate overview on Wednesday, June 19, from 10:55 AM
June 5, 2019 Progenity Strengthens Executive Team with the Addition of Eric d’Esparbes as Chief Financial Officer
Announcing our new Senior Vice President and Chief Financial Officer (CFO). SAN DIEGO—June 5, 2019 —Progenity, Inc., a privately held biotechnology company, today announced the hire of Eric d’Esparbes as Senior Vice President and Chief Financial Officer (CFO). Mr.
May 22, 2019 Progenity Presents Proof-of-Concept Data on Proprietary Ingestible Technologies for Gastrointestinal Disorders
We announced results from three studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies. SAN DIEGO—May 22, 2019 —Progenity, Inc., a privately held biotechnology company developing proprietary precision
May 7, 2019 Progenity Featured in GenomeWeb
Highlighting the Resura® Prenatal Test Progenity was featured in  GenomeWeb  highlighting our newest cfDNA option, the Resura ®  Prenatal Test, which provides custom-designed testing for families with rare disease. See the  full article  in  GenomeWeb  for our recent developments in the noninvasive
May 6, 2019 Progenity to Showcase New Data at Digestive Disease Week®
Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, this week announced three upcoming poster presentations. SAN DIEGO—May 6, 2019 –Progenity, Inc., a privately
April 2, 2019 Progenity launches first commercially available, custom-designed, noninvasive prenatal test for monogenic diseases
Progenity also announces improvements to its Innatal® noninvasive prenatal test (NIPT), demonstrating market-leading sensitivity and specificity across all common chromosomal aneuploidies. SAN DIEGO, April 2, 2019  – Progenity, Inc., a privately held biotechnology company, announced today the
April 1, 2019 Novel cell-free DNA testing for monogenic disease
Zoom in from full chromosome to single nucleotide with a new application for cell-free DNA (cfDNA) technology. Expand your patients’ prenatal options with the Resura™ Prenatal Test. Current practice for diagnosing a fetus at-risk of an inherited disease involves undergoing invasive procedures.
February 26, 2019 Progenity to present at three key investor conferences
Presenting at the BTIG, Raymond James, and Cowen health care conferences. SAN DIEGO, February 26, 2019  – Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms,
Displaying 21 - 30 of 33